The latest news from Sutura
Stay up-to-date with Sutura Therapeutics' latest innovations and advancements by visiting our newsroom regularly.
The Promise of Stabilised CPPs in Intracellular Delivery
Explore how Sutura Therapeutics' innovative stabilised CPPs are revolutionising intracellular delivery of macromolecular payloads.
The Urgent Need for Better Therapies: Tackling the Challenges of Pompe Disease
Learn about groundbreaking efforts to revolutionise Pompe disease treatment and improve patient outcomes in the face of current therapy limitations.
A Successful BioTrinity 2024 for Sutura
Discover how Sutura's groundbreaking research at BioTrinity 2024 is setting the stage for advances in healthcare and biotechnology.
Sutura Therapeutics at BioTrinity 2024
Join our CEO, Edwin Wagena, at BioTrinity 2024 to explore the future of biotech and discover more about our cutting-edge drug conjugate platform.
PeptiGos, a Next Generation CPP Platform
After 40 years, cell-penetrating peptides are finally realising their potential - Dr Wouter Eilers of Sutura explains how Sutura’s PeptiGo platform aims to perfect delivery.
Sutura Therapeutics Completes Investment Round
BREAKING: Sutura Therapeutics, a private biopharmaceutical company developing peptide-based biomolecular medicinal products, completes seed investment round.
Sutura Partners with Cybersecurity Specialist Mitigo
Sutura has teamed up with cybersecurity specialist Mitigo Group to access top-tier cybersecurity services.
Ask Us Anything!
Do you have a question about the innovative technology behind Sutura’s groundbreaking Drug Conjugate Platform? We’re so glad you asked!